Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

World News: . []

EAGAN Minn April 16 2018 GLOBE NEWSWIRE -- Biothera Pharmaceuticals Inc today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biotheras Imprime PGG with KEYTRUDA pembrolizumab an an ti-PD-1...

More news and information about Biothera Pharmaceuticals, Inc.

Published By:

Globe Newswire: 14:00 GMT Monday 16th April 2018

Published: .

Search for other references to "biothera" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us